This is a promotional webinar funded and organised by Besins Healthcare (UK) Limited

New treatment option for vaginal atrophy

NEW Imvaggis (estriol) 0.03mg pessary

7pm, Wednesday 20 November 2019

Register now

Free webinar

Besins Healthcare (UK) Ltd cordially invite you to attend a FREE webinar. Join Dr Anne Connolly, Dr Sarah Gray and Dr Paula Briggs as they discuss vaginal atrophy and a new treatment option that can treat the local vaginal symptoms associated with oestrogen deficiency in postmenopausal women, alleviating inflammatory disorders and restoring the vaginal Lactobacillus flora.1 

These leading women’s health experts will explore:

  • Vaginal atrophy, its prevalence and links to menopause
  • The impact of vaginal atrophy on women’s lives
  • An introduction to Imvaggis (estriol) 0.03mg pessary
  • The clinical data, main features and benefits
  • Patient profiles

There will also be an opportunity to put questions to the speakers. Register today to learn about this new solution for improving the quality of life of post menopausal women experiencing vaginal atrophy.

References
1. Imvaggis Summary of Product Characteristics.

What is vaginal atrophy?

Vaginal atrophy is a common condition associated with a lack of oestrogen in the vaginal tissues, which occurs during the menopause.As oestrogen receptors are present on the vagina, urethra, bladder trigone and the pelvic floor, all of these areas can be affected.The term ‘urogenital atrophy’ may also be used when oestrogen depletion results in changes to the urinary tract as well as the vagina.In a survey of 3768 postmenopausal women from Western Europe, over 60% reported symptoms of vaginal atrophy.4

References

1. Mac Bride
2. PCWHF
3. Evans 2007
4. Nappi 2016 Climacteric

New Imvaggis (estriol) 0.03mg pessary has been designed with the patient in mind. Imvaggis is an ultra-low-dose, smooth pessary that is easily inserted without the need for an applicator.

Imvaggis effectively treats the local vaginal symptoms associated with oestrogen deficiency in postmenopausal women, significantly improving the symptoms of vaginal atrophy and the physiology of the vaginal epithelium vs placebo (p<0.001). 1,2

References
1. Imvaggis Summary of Product Characteristics.
2. Griesser H et al. Maturitas. 2012;71:360-8.

Speakers

Dr Anne Connolly

GPwSI Gynaecology, Bradford

Having survived a two year posting to a mission hospital in Zimbabwe, Anne returned to General Practice in inner-city Bradford in 1990 and currently works as a GP providing care for asylum seekers, refugees, homeless and sex workers.

She is a GPSI in gynaecology, accredited as a hysteroscopist, colposcopist and FSRH trainer.  She is also a Bradford City CCG clinical board member with remit for maternity, women’s, children and young people’s healthcare.

Anne is chair of the Primary Care Women’s Health Forum and RCGP Clinical Champion for Women’s Health.  She is also co-editor of Women’s Health in Primary Care. 

Dr Sarah Gray

GP specialist in women’s health, Cornwall

Sarah Gray has spent the last 30 years delivering Women’s Health in Primary Care. She ran an NHS menopause referral service until 2016 providing secondary and tertiary level advice. This was decommissioned to save funding costs and she continues this work in the private sector.

She sat on the British Menopause Society Council for 10 years and is now a director of the Primary Care Women’s Health Forum. She was a member of the groups who developed NICE guidance and quality standards for Heavy Menstrual Bleeding. She teaches at all levels from practical one-to-one sessions in general practice to webinars and international congresses.

Dr Paula Briggs

Consultant, Sexual & Reproductive Health, Southport

Paula Briggs is a Consultant in Sexual & Reproductive Health. She is the lead for the Community Sexual Health Service in Sefton and Trust lead for Community Gynaecology and Menopause.

She is Co-editor of Managing the Menopause, 21st Century Solutions, published by Cambridge University Press and has just completed a patient handbook on the Menopause, published by Karger.

She was recently elected to the Council of the British Menopause Society.

Register

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd, Drug Safety on 0203 862 0920 Email: pharmacovigilance@besinshealthcare.com

Job code: IMV/2019/004

This is a promotional webinar funded and organised by Besins Healthcare (UK) Limited

Date of preparation: September 2019

The link you have selected will take you away from this site to one that is not owned or controlled by Besins Healthcare (UK) Limited. Besins Healthcare (UK) Limited makes no representation as to the accuracy of the information contained on sites we do not own or control. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.